Immunic (IMUX) Expected to Post Earnings on Thursday

Immunic (NASDAQ:IMUX) is anticipated to release its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to post earnings of ($1.1648) per share for the quarter. Interested persons may visit the the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, August 6, 2026 at 9:30 AM ET.

Immunic (NASDAQ:IMUX) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($1.08) EPS for the quarter, missing the consensus estimate of ($0.71) by ($0.37). On average, analysts expect Immunic to post $-5 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Immunic Trading Up 0.9%

Immunic stock opened at $14.10 on Tuesday. The firm has a market cap of $192.04 million, a P/E ratio of -2.53 and a beta of 1.41. Immunic has a 1-year low of $5.06 and a 1-year high of $15.84. The firm has a 50-day moving average of $14.31 and a 200-day moving average of $11.56.

Analyst Ratings Changes

A number of research firms have commented on IMUX. Stifel Nicolaus set a $25.00 price target on Immunic and gave the company a “buy” rating in a research report on Thursday, April 16th. LADENBURG THALM/SH SH upgraded Immunic to a “strong-buy” rating in a research report on Wednesday, July 29th. Roth Capital reissued a “buy” rating and set a $19.00 target price on shares of Immunic in a research note on Thursday, May 14th. Weiss Ratings restated a “sell (d-)” rating on shares of Immunic in a report on Friday, May 29th. Finally, Wolfe Research initiated coverage on Immunic in a research note on Friday, May 22nd. They issued an “outperform” rating for the company. Three analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $47.57.

Institutional Trading of Immunic

Several institutional investors and hedge funds have recently bought and sold shares of IMUX. XTX Topco Ltd bought a new stake in Immunic during the 4th quarter valued at approximately $120,000. Millennium Management LLC lifted its stake in shares of Immunic by 544.6% in the 4th quarter. Millennium Management LLC now owns 3,419,299 shares of the company’s stock valued at $1,825,000 after purchasing an additional 2,888,829 shares during the period. Laurion Capital Management LP lifted its stake in shares of Immunic by 106.3% in the 4th quarter. Laurion Capital Management LP now owns 3,882,162 shares of the company’s stock valued at $2,072,000 after purchasing an additional 2,000,000 shares during the period. Squarepoint Ops LLC boosted its position in shares of Immunic by 29.9% during the fourth quarter. Squarepoint Ops LLC now owns 352,875 shares of the company’s stock valued at $188,000 after purchasing an additional 81,301 shares in the last quarter. Finally, Nantahala Capital Management LLC bought a new stake in shares of Immunic during the fourth quarter valued at approximately $2,337,000. 51.82% of the stock is currently owned by hedge funds and other institutional investors.

Immunic Company Profile

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.